Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 by Forouzanfar, MH et al.
Copyright 2017 American Medical Association. All rights reserved.
Global Burden of Hypertension and Systolic Blood Pressure
of at Least 110 to 115mmHg, 1990-2015
Mohammad H. Forouzanfar, PhD; Patrick Liu, BS; Gregory A. Roth, MD; Marie Ng, PhD; Stan Biryukov, BS; Laurie Marczak, PhD;
Lily Alexander, BA; Kara Estep, MPA; Kalkidan Hassen Abate, MS; Tomi F. Akinyemiju, PhD; Raghib Ali, FRCP; Nelson Alvis-Guzman, PhD;
Peter Azzopardi, MEpi; Amitava Banerjee, DPhil; Till Bärnighausen, MD; Arindam Basu, PhD; Tolesa Bekele, MPH; Derrick A. Bennett, PhD;
Sibhatu Biadgilign, MSc; Ferrán Catalá-López, PhD; Valery L. Feigin, PhD; Joao C. Fernandes, PhD; Florian Fischer, MPH;
Alemseged Aregay Gebru, MPH; Philimon Gona, PhD; Rajeev Gupta, PhD; Graeme J. Hankey, MD; Jost B. Jonas, MD; Suzanne E. Judd, PhD;
Young-Ho Khang, MD; Ardeshir Khosravi, PhD; Yun Jin Kim, PhD; RuthW. Kimokoti, MD; Yoshihiro Kokubo, PhD; Dhaval Kolte, PhD; Alan Lopez, PhD;
Paulo A. Lotufo, DrPH; Reza Malekzadeh, MD; Yohannes AdamaMelaku, MPH; George A. Mensah, MD; AwokeMisganaw, PhD; Ali H. Mokdad, PhD;
Andrew E. Moran, MD; Haseeb Nawaz, MD; Bruce Neal, PhD; Frida Namnyak Ngalesoni, MSc; Takayoshi Ohkubo, MD; Farshad Pourmalek, PhD;
Anwar Rafay, MS; Rajesh Kumar Rai, MPH; David Rojas-Rueda, PhD; Uchechukwu K. Sampson, MD; Itamar S. Santos, PhD; Monika Sawhney, PhD;
Aletta E. Schutte, PhD; Sadaf G. Sepanlou, PhD; Girma Temam Shifa, MPH; Ivy Shiue, PhD; Bemnet Amare Tedla, BS; Amanda G. Thrift, PhD;
Marcello Tonelli, MD; Thomas Truelsen, DMSc; Nikolaos Tsilimparis, PhD; Kingsley Nnanna Ukwaja, MD; Olalekan A. Uthman, PhD;
Tommi Vasankari, PhD; Narayanaswamy Venketasubramanian, FCRP; Vasiliy Victorovich Vlassov, MD; Theo Vos, PhD; RonnyWesterman, PhD;
Lijing L. Yan, PhD; Yuichiro Yano, MD; Naohiro Yonemoto, MPH; Maysaa El Sayed Zaki, PhD; Christopher J. L. Murray, DPhil
IMPORTANCE Elevated systolic blood (SBP) pressure is a leading global health risk.
Quantifying the levels of SBP is important to guide prevention policies and interventions.
OBJECTIVE To estimate the association between SBP of at least 110 to 115 mmHg and SBP of
140mmHg or higher and the burden of different causes of death and disability by age and
sex for 195 countries and territories, 1990-2015.
DESIGN A comparative risk assessment of health loss related to SBP. Estimated distribution of
SBP was based on 844 studies from 154 countries (published 1980-2015) of 8.69million
participants. Spatiotemporal Gaussian process regression was used to generate estimates of
mean SBP and adjusted variance for each age, sex, country, and year. Diseases with sufficient
evidence for a causal relationship with high SBP (eg, ischemic heart disease, ischemic stroke,
and hemorrhagic stroke) were included in the primary analysis.
MAIN OUTCOMES ANDMEASURES Mean SBP level, cause-specific deaths, and health burden
related to SBP (110-115 mmHg and also140mmHg) by age, sex, country, and year.
RESULTS Between 1990-2015, the rateof SBPof at least 110 to 115mmHg increased from73 119
(95%uncertainty interval [UI], 67949-78241) to81 373 (95%UI, 76814-85 770)per 100000,
andSBPof 140mmHgorhigher increased from 17 307 (95%UI, 17 117-17 492) to20526 (95%UI,
20283-20746)per 100000.Theestimatedannual death rateper 100000associatedwith
SBPof at least 110 to 115mmHg increased from 135.6 (95%UI, 122.4-148.1) to 145.2 (95%UI
130.3-159.9) and the rate for SBPof 140mmHgorhigher increased from97.9 (95%UI, 87.5-108.1)
to 106.3 (95%UI, 94.6-118.1). Loss of disability-adjusted life-years (DALYs) associatedwith SBPof
at least 110 to 115mmHg increased from 148million (95%UI, 134-162million) to211million (95%
UI, 193-231million), and for SBPof 140mmHgorhigher, the loss increased from95.9million
(95%UI, 87.0-104.9million) to 143.0million (95%UI, 130.2-157.0million). The largest numbers of
SBP-relateddeathswere causedby ischemicheart disease (4.9million [95%UI, 4.0-5.7million];
54.5%), hemorrhagic stroke (2.0million [95%UI, 1.6-2.3million]; 58.3%), and ischemic stroke
(1.5million [95%UI, 1.2-1.8million]; 50.0%). In 2015, China, India, Russia, Indonesia, and the
UnitedStates accounted formore thanhalf of theglobalDALYs related toSBPof at least 110 to
115mmHg.
CONCLUSIONS AND RELEVANCE In international surveys, although there is uncertainty in some
estimates, the rate of elevated SBP (110-115 and140mmHg) increased substantially
between 1990 and 2015, and DALYs and deaths associated with elevated SBP also increased.
Projections based on this sample suggest that in 2015, an estimated 3.5 billion adults had SBP
of at least 110 to 115 mmHg and 874million adults had SBP of 140mmHg or higher.
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S ystolic blood pressure (SBP) of at least 110 mm Hg hasbeen related to multiple cardiovascular and renal out-comes, including ischemicheart disease, cerebrovascu-
lar disease, and chronic kidney disease.1-3 The global obesity
epidemic may further increase SBP in some populations.4-6
The burden of SBP of at least 110mmHg remains high despite
the availability of preventive interventions and low-cost, ef-
fective antihypertensive medications.4,7
Several studies have assessed SBP measurements from
population-based examination surveys.4,5 The global bur-
den related to high SBP has been reported in detail for
1997, 2001, 2005, and 2010.5,6,8,9 Results from the Global
Burden of Disease, Injuries, and Risk Factor study 2015
(GBD 2015) related risk factors to 41% of all disability-
adjusted life-years (DALYs) in 2015.10 In GBD 2015, SBP was
associated with the highest burden among risk factors—more
than either smoking or obesity.10 In the current study, we
used the results of the GBD 2015 comparative risk assess-
ment to explore patterns of SBP above 110 to 115 mm Hg and
related deaths and DALYs for 195 countries and territories
from 1990 to 2015.10 This analysis reports separately the dis-
ease burden for participants aged 25 years and older related
to SBP levels of at least 110 to 115 mm Hg and SBP levels of
140 mmHg or higher.11,12
This analysis supersedes all previous global burdenofdis-
ease study results for SBP because all data from 1990 to pres-
ent have been re-analyzed using consistent methods.
Methods
This analysis was part of the GBD 2015 comparative risk
assessment to assess health loss (DALYs) related to specific
risk factors.9 In contrast to pooling studies or primary studies
that analyze individual record data to estimate the magni-
tude of related burden and the number of people at different
levels of SBP, the GBD study is a descriptive meta-analysis of
available study results. Thus, the data are projections for
a population rather than direct estimates for a sample pop-
ulation and should be assessed considering the availability
of primary data for a given country and year, uncertainty of
the pooled estimates, and the overall modeling strategy
and assumptions.
Prior to the 1990s, diastolic blood pressure was consid-
ered to be a better predictor of health outcomes than SBP.
Later, epidemiological studies showed a greater association
and better predictive validity with outcomes for SBP, espe-
cially for patients who were older (in whom incidence of
related disease is higher).13,14 Atherosclerosis is known to
increase SBP and strengthen the association with heart, cen-
tral nervous system, and renal vascular diseases.15-17 Due to
the strong correlation between SBP and diastolic blood pres-
sure and to avoid double counting of high blood pressure
burden, measures of SBP alone are now used in studies of the
global and national burdens of risk factors. Only SBP was
included in this analysis. For this study, estimates were first
produced at age-, sex-, country-, year-, and cause-specific
strata before being aggregated.
The analysis was divided into 5 components in the
following sequence: (1) the distribution (mean and variance)
of SBP in each age, sex, and country group was estimated;
(2) the relative risks (RRs) of 10 cardiovascular and renal
outcomes, including chronic kidney disease, associated
with SBP of at least 110 to 115 mm Hg based on pooled pro-
spective cohort studies were estimated; (3) a level of mini-
mum risk for SBP was determined; (4) the cause-specific
population-attributable fraction (PAF) related to SBP that
was elevated above this minimum level of risk was calcu-
lated; and (5) deaths and DALYs related to SBP of at least 110
to 115 mm Hg were computed by multiplying each outcome
by the PAF for each country, age, sex, and year group.
Estimating SBP Distributions
Data for this study were obtained from an update to
the systematic review of health examination surveys re-
porting SBP originally conducted as part of the GBD
2010 study.9,18 Using PubMed, studies published between
July 15, 2009, and December 31, 2015, were added to the
original review. Studies were included if they were
population-based and measured SBP using a sphygmoma-
nometer (either manual or electronic; see eAppendix in
the Supplement for details on the evaluation of study qual-
ity and identifying and removing outliers). All measure-
ments of blood pressure were categorized by sex, and data
points were divided by age groups based on the global age
distribution of mean SBP using the available detailed age-
and sex-specific data. Mean SBP was estimated in each
age-, sex-, country-, and year-specific stratum using spatio-
temporal Gaussian process regression (method has been
widely applied in global health estimation, including for
tobacco prevalence estimation and obesity).19,20 Detailed
methods for this estimation procedure are described in the
eAppendix (Supplement) and country data sources are pro-
vided in searchable form online through the Global Health
Data Exchange.21
Key Points
Question What is the worldwide association between elevated
blood pressure and the burden of disease?
Findings In studies from 154 countries that included 8.69 million
participants, it is estimated that between 1990 and 2015
the rate of systolic blood pressure (SBP) of at least 110
to 115 mm Hg increased from 73 119 to 81 373 per 100000
persons, and SBP of 140 mmHg or higher increased from 17 307
to 20 526 per 100000 persons. The estimated rate of annual
deaths associated with SBP of of at least 110 to 115 mm Hg
increased from 135.6 to 145.2 per 100000 persons, and for SBP
of 140 mmHg or higher increased from 97.9 to 106.3 per
100000 persons.
Meaning Over the past 25 years, the number of individuals
with worldwide SBP levels of at least 110 to 115 mmHg and
of 140mmHg or higher and the estimated associated deaths
have increased substantially.
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Accounting for Blood Pressure Variation
ThestandarddeviationofSBPwasestimated foreveryage, sex,
country, and year by estimating the relationship between the
mean of SBP and the standard deviation in available studies;
the proportion of variance of SBP due to measurement error
was also estimated (eAppendix in the Supplement).22-27 SBP
variesover timewith circadian rhythm, changes indiet, physi-
cal activity, andtreatment,whichaddsubstantial randomnoise
to the long-term exposure average.28 Randommeasurement
error of SBP also causes an attenuation of the association be-
tween the SBP level and incidence of disease outcomes called
regression dilution bias.29 A correction for usual SBP is com-
monly used in cohort studies to estimate the association be-
tween the level of SBP and the outcome risk. Using these cor-
rected RRs in burden of disease estimates requires the same
adjustment be applied to the distributions of SBP from sur-
veys that are based on 2 to 3 measurements taken during a
single encounter. Multiple measurements in a cohort of par-
ticipants over time can provide an estimate of the random
variation that needs to be taken out of the single (time) mea-
surement to correct for this underestimation of effect size.
Relative Risks for Outcomes Related to SBP
TheGBDcomparativeriskassessmentframeworkpairseachrisk
withknowndisease-specificoutcomes.Tobepaired, sufficient
evidence foracausal relationshipbetweenriskanddiseaseout-
comeisneeded.Thestrengthofevidenceforassociationbetween
risk-outcome pairs, including elevated SBP, was evaluated as
part of the GBD 2015 study (see eAppendix in the Supplement
fordetailedmethodsof the risk-outcomeevaluation).10On the
basisofanalysis frompooledcohortstudies,30 thefollowingdis-
easeswere identifiedashavingsufficientevidence to support a
relationshipwithhighSBP(≥110-115mmHg): ischemicheartdis-
ease, ischemic stroke, hemorrhagic stroke, hypertensive heart
disease, cardiomyopathy, atrial fibrillation, aortic aneurysm,
rheumaticheartdisease, peripheral vasculardisease, endocar-
ditis, chronickidneydisease, andothercardiovasculardiseases
(CVDs [cardiovascular outcomes other than those previously
listed]).Although thecauseof rheumaticheartdiseaseanden-
docarditis is infection,highSBPhasbeenassociatedwithan in-
creasing riskofdeath, acceleratingadverseheart effects caused
by infectionorautoimmuneresponse.Theaggregatedoutcome
was assumed to include death andmorbidity.
Cohort studies and ameta-analysis of 147 clinical trials of
blood pressure–lowering drugs found improved outcomes
due to blood pressure lowering were similar across the range
of 120 to 180mmHg SBP levels at pretreatment.31,32 The RRs
that were based on blood pressure lowering in these meta-
analyseswere similar to the results fromtheProspective Stud-
iesCollaboration.33 For thepresent study, age-specific RRs for
cardiovascular outcomesbasedonpooled cohort studieswere
used including the Prospective Studies Collaboration and the
AsiaPacificCohort StudiesCollaboration (eFigure 1 andeTable
1 in the Supplement).18,34 For this study, a meta-analysis of
cohort studieswas completed to estimate the relationship be-
tween SBP and chronic kidney disease. Citation information
for the data sources used for RRs are provided by the Global
Health Data Exchange in a searchable web tool.21
MinimumRisk Level
The GBD comparative risk assessment framework is based on
the observation that risk caused by a given exposure begins at
acertain levelandthenascendsasexposure increasesabovethat
level. This counterfactual level is referred to as the theoretical
minimum-risk exposure level which, when comparedwith an
observedlevelofSBP,allowsforestimationofthePAF.Thetheo-
retical minimum-risk exposure level of SBP was estimated to
range from 110 to 115 mmHg based on pooled prospective co-
hort studies that showriskofmortality increases for SBPabove
that level.30,35 Recent randomized clinical trial results, includ-
ing theSystolicBloodPressure InterventionTrial (SPRINT)and
theHeartOutcomesPreventionEvaluation(HOPE-3), showthat
lifestylemodificationearly in life is likely tobeamajor compo-
nent for loweringSBP tonear this level given thevariable range
of benefit observed in these studies when blood pressure was
loweredwithantihypertensivemedications alone.36-38The se-
lectionof a theoreticalminimum-risk exposure level of an SBP
level of 110 to 115 mm Hg—the level that captures the maxi-
mum attributable burden—is consistent with the GBD study
approachofestimatingall attributablehealth loss that couldbe
prevented even if current interventions did not exist that
could achieve such a change in exposure level (eg, a tobacco-
smokingprevalenceof0%).Somestudies, suchas theFraming-
hamcohort, have foundan increase in SBPwith increasing age
and ithasbeensuggestedthat the theoreticalminimum-riskex-
posure level should also follow this age pattern.39 Other stud-
ies that found no change in SBP with age40-42 support main-
taining a single theoretical minimum-risk exposure level
across age groups. Based on the current evidence,43 we deter-
mined that a difference in theoreticalminimum-risk exposure
level by age groupwas not sufficiently supported and decided
to retain a single level across age groups. Further investiga-
tions in the formofcohortsorpooledcohort studiesareneeded
to determine if varying the theoretical minimum-risk expo-
sure level for SBPwithagegroup is justified.To include theun-
certainty in the theoretical minimum-risk exposure level,
1000randomdraws fromtheuniformdistributionof the inter-
val between 110 and 115 mmHg were taken; unertainty in the
theoretical minimum-risk exposure level was propagated by
sampling between the 110- and 115-mmHg interval each time
the population-attributable burdenwas calculated.
Population-Attributable Fractions
Theequation inthissectiondescribes theformulausedforcom-
puting a PAF for a continuous risk factor; the PAF for SBP in an
age-sex-country-year for a cause (o) is defined as follows:
PAFoasct =
u
x = l
RRoas(x)Pasct(x)dx − RRoas(theoretical 
minimum-risk exposure level)
u
x = l
RRoas(x)Pasct(x)dx
.
RRoas(x) is the relative risk as a function of exposure level (x)
for SBP, cause (o), age group (a) and sex (s). Pasct (x) is
the distribution of exposure of SBP in age group (a), sex (s),
country (c), and year (t). The lowest level of exposure (l) and
thehighest level of exposurepossible (u) (300mmHg) are also
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described in this equation. The log-normal function, rather
thannormal,44 β, or γdistributions, gave thebest fit of thedis-
tribution of SBP inmultiple health examination surveys such
as the US National Health and Nutrition Examination Survey
(NHANES),ChinaLongitudinalHealthyLongevitySurvey, and
Indonesia Family Life Survey.
Burden Related to SBP
Deaths and DALYs related to SBP of at least 110 to 115 mmHg
were computed bymultiplying an age-, sex-, country-, year-,
and cause-specific PAF by the estimated deaths or DALYs for
the same strata. Total (all-causes) burden related to SBP of at
least 110 to 115 mmHg was calculated by the following:
All-cause−associated burdenasct =w
o = 1
DALYoasct PAFoasct .
Hypertensive heart disease and hypertensive chronic kidney
disease were treated as conditions that would not have oc-
curred without elevated systolic blood pressure, and all dis-
ease burden for these causes was attributed to this risk fac-
tor. The PAFs and related deaths andDALYs for each 1-mmHg
increment of SBP were evaluated to provide the distribution
of health burden across the range of possible SBP levels.
Uncertainty Intervals
We computed 95% uncertainty intervals (UIs) for all esti-
mates of deaths and DALYs related to SBP of at least 110 to
115 mm Hg. A Monte Carlo simulation approach was used
to propagate uncertainty from all sources in the final burden
estimations. These intervals incorporated sampling uncer-
tainty in theexaminationsurveys,parameter estimation in the
spatiotemporal Gaussian process regression model for blood
pressuremean, theRRs for eachoutcome from the analysis of
pooled cohort studies, the theoretical minimum-risk expo-
sure level, and the deaths and DALYs estimated for each age,
sex, country, year, and cause. The 1000 draws of the poste-
rior distribution of mean SBP and outcomes by country, age,
and sex were calculated independently so the variance of
estimation for the aggregate groups (eg, all-age, both sexes,
or global burden) were more likely to be underestimated be-
cause of possible covariance betweendifferent risk levels and
outcome, countries, or sexes.Despite efforts to incorporate all
sources of uncertainty, uncertainties from some intermedi-
ate predictive steps were not propagated due to existing data
and methodological constraints. Therefore, the UIs pre-
sented may be optimistic estimates. Analyses and computa-
tionswere completedusing Stata version 13.1, R version 3.1.2,
and Python version 2.7.11.
Results
Global
In total, 844 studies from 154 countries (N=8.69million indi-
vidual participants) published from 1980 to 2015 were in-
cluded inGBD2015.10 Between 1990and2015, the rate of SBP
of at least 110 to 115 mm Hg increased from 73 119 (95% UI,
67949-78241) to 81 373 (95%UI, 76814-85 770) per 100000;
the rate of SBP of 140mmHg or higher increased from 17 307
(95% UI, 17 117-17 492) to 20526 (95% UI, 20283-20746) per
100000. The associated estimated annual deaths for SBP of
at least 110 to 115 mm Hg and of 140 mm Hg or higher in-
creased from135.6deaths (95%UI, 122.4-148.1) to 145.2deaths
(95% UI 130.3-159.9) per 100000 and from 97.9 deaths (95%
UI,87.5-108.1) to 106.3deaths (95%UI,94.6-118.1)per 100000.
Table 1 shows the projected number of individuals,
deaths, and DALYs related to SBP of at least 110 to 115 mm Hg
and SBP of 140 mm Hg or higher for 6 time points between
1990 and 2015. The projected number of individuals with
SBP of at least 110 to 115 mm Hg increased from 1.87 billion
(95% UI, 1.74-2.0 billion) in 1990 to 3.47 billion (95% UI, 3.27-
3.65 billion) in 2015, and the associated annual number of
projected deaths increased from 7.2 million (95% UI, 6.5-7.9
million) in 1990 to 10.7 million (95% UI, 9.6-11.8 million) in
2015, a 1.6% increase per year (Table 1). Projected DALYs
related to SBP of at least 110 to 115 mm Hg increased from
148 million (95% UI, 134-162 million) in 1990 to 211 million
(95% UI 193-231 million) in 2015. The projected number of
individuals with SBP of 140 mm Hg or higher increased from
442 million (95% UI, 437-447 million) in 1990 to 874 million
(95% UI, 864-884 million) in 2015, and the associated annual
number of projected deaths in 2015 (7.8 million [95% UI, 7.0-
8.7 million]) or 14.0% of total deaths (95% UI, 12.5%-15.5%)
and 143 million DALYs (95% UI, 130.2-157.0 million) were
related to SBP of 140 mmHg or higher.
Similar to DALYs, age-standardized death rates associ-
ated with SBP of at least 110 to 115 mmHg declined from 225
(95% UI, 200-247) per 100000 to 170 (95% UI, 151-188) per
100000 (eTable 4 in the Supplement), which suggests popu-
lation growth and agingmayhave been themain driver of the
observed increase in total projectedDALYs related toSBPof at
least 110 to 115mmHg since 1990 (Table 1). Age-standardized
rate per capita (an adjusted measure for population size and
age structure) of deaths and DALYs related to SBP of at least
110to115mmHgdecreaseddespite increasedaverageSBP.The
downward change in the age-standardized rate of deathswas
0.92%(95%UI,0.80%-1.03%)peryear formenand1.37%(95%
UI, 1.26%-1.50%) per year forwomen (eTable 6 in the Supple-
ment). Age-standardized DALYs per capita decreased from
4.1 (95% UI, 3.7-4.5) per 100 persons in 1990 to 3.2 (95% UI,
2.9-3.4) per 100 persons in 2015 (see data reported as per
100000 individuals in eTable 4 in the Supplement).
Figure 1 shows2viewsofglobal trends for individualswith
SBPof 140mmHgorhigher.PanelAshows that the rateofhigh
SBP of 140 mm Hg or higher increased from 17 307 (95% UI,
17 116.9-17492)per 100000 in 1990 to20525 (95%UI, 20283-
20 746) per 100000 in 2015. Although the rate initially de-
creased between 1990 and 1995, the initial trend was fol-
lowed by an increase to 2015. Panel B shows that after
controlling for changes in population aging, the age-
standardized rate increased after 2000 (eFigure 2 and eFig-
ure 3 in the Supplement).
Figure 2 shows the distribution of DALYs in the world by
level of SBP and by cause. At the global level, 29% of DALYs
related to SBP of at least 110 to 115 mm Hg occurred in
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individuals who had SBP between 115 and 140 mm Hg. An-
other 26% of DALYs occurred in individuals with SBP be-
tween 140 and 150 mmHg, and the remaining 45% of DALYs
occurred in individuals with SBP 150 mmHg or higher. At all
levels of SBP, ischemic heart disease was themost important
contributor to SBP-related deaths followed by hemorrhagic
stroke and then ischemic stroke.
Projected global deaths andDALYs associatedwith SBPof
at least 110 to 115 mmHg and SBP of 140 mmHg or higher by
specific outcomeand thePAFs for those outcomes in 2015 are
shown in Table 2. Forty-one percent (95% UI, 35.9%-45.4%)
of deaths related to SBP of 140mmHg or higher were related
toCVDs (and the rest through chronic kidneydisease), among
which 40.1% (95%UI, 32.2%-48.1%)were related to ischemic
heart disease, 40.4% (95% UI, 34.5%-46.4%) to cerebrovas-
culardiseases (38.1%[95%UI,29.9%-46.7%] to ischemicstroke
and 42.5% [95% UI, 34.2%-50.8%] to hemorrhagic stroke)
(death PAFs for SBP ≥140mmHg; Table 2). SBP of at least 110
to 115 mmHg was associated with all hypertensive heart dis-
ease deaths, 68.7% (95% UI, 63.7%-73.5%) of chronic kidney
disease deaths, 54.4% (95%UI, 46.8%-62.4%) of cerebrovas-
cular disease deaths (50.0% [95% UI, 39.4.0%-60.8%] of is-
chemic stroke and 58.3% [95% UI, 48.0%-68.5%] of hemor-
rhagic stroke deaths), and 54.5% (95% UI, 44.4%-64.2%) of
ischemic heart disease deaths (Table 2). Overall, SBP of
140 mm Hg or higher was associated with 73.2% (95% UI,
Figure 1. Projected Global Rates of Systolic Blood Pressure of 140mmHg or Higher
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Reported data are for both sexes combined and for individuals aged 25 years and older. Shading indicates 95% uncertainty intervals.
Table 1. Projected Number of Individuals GloballyWith Systolic Blood Pressure of at Least 110 to 115mmHg and of 140mmHg or Higher,
Deaths, and Disability-Adjusted Life-Years, 1990-2015a
Projected No. (95% Uncertainty Interval)
1990 1995 2000
SBP ≥110-115 mm Hg
Individuals, thousands 1 868 253 (1 736 165-1 999 123) 2 119 822 (1 967 808-2 270 838) 2 427 524 (2 259 371-2 591 634)
Deaths, thousands 7191 (6493-7852) 7946 (7187-8702) 8514 (7684-9329)
DALYs, thousands 147 625 (134 192-161 520) 163 476 (148 256-178 742) 175 618 (159 592-191 887)
SBP ≥140 mm Hg
Individuals, thousands 442 214 (437 354-446 928) 478 941 (473 708-484 088) 535 993 (530 228-541 646)
Deaths, thousands 5191 (4641-5731) 5670 (5054-6266) 6014 (5382-6658)
DALYs, thousands 95 900 (86 962-104 856) 105 249 (95 326-115 157) 112 630 (102 225-123 351)
2005 2010 2015
SBP ≥110-115 mm Hg
Individuals, thousands 2 752 925 (2 577 041-2 924 177) 3 104 244 (2 922 179-3 281 536) 3 466 261 (3 272 051-3 653 550)
Deaths, thousands 9212 (8326-10 101) 9826 (8835-10 790) 10 704 (9601-11 787)
DALYs, thousands 189 579 (172 703-206 696) 198 389 (180 979-216 006) 211 816 (192 712-231 114)
SBP ≥140 mm Hg
Individuals, thousands 619 320 (613 021-626 064) 743 995 (736 480-752 041) 874 332 (864 013-883 705)
Deaths, thousands 6531 (5842-7225) 7103 (6338-7840) 7834 (6973-8706)
DALYs, thousands 123 241 (111 943-134 737) 132 018 (120 214-144 095) 143 037 (130 198-156 961)
Abbreviation: DALYs, disability-adjusted life years; SBP, systolic blood pressure.
a All data are for individuals aged 25 years and older and both sexes combined.
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71.5%-75.0%) of all SBP-related deaths of at least 110 to
115 mm Hg, or 14.0% (95% UI, 12.5%-15.5%) of global deaths
(Table 2).
Table 3 showsprojecteddeaths andDALYsassociatedwith
SBP 110 to 115 mmHg and higher and SBP of 140 mmHg and
higher by age and sex. With increasing cardiovascular DALYs
as reportedbyage, SBP-relateddeathsandDALYs increase sub-
stantially (Table 3). Deaths andDALYS increasedby agebegin-
ning with 2.5 million DALYs related to SBP of at least 110 to
115 mmHg for men aged 25 to 29 years, 1.1 million DALYs for
women in that age group, and increasing to 11.0millionDALYs
for men aged 80 years and older, and 15.6 million DALYs for
women in that age group. The total burden is greater in men
than women except after age 75, when more burden is ob-
served in women because of longer life expectancy. Among
those aged 60 years and older, more than 66% of burden is in
Table 2. Projected Number of Global Deaths and Disability-Adjusted Life-Years Related to Systolic Blood Pressure of at Least 110 to 115mmHg
and of 140mmHg or Higher and Population-Attributable Fractionsa
Systolic Blood Pressure
≥110 to 115 mm Hg ≥140 mm Hg
Deaths,
No. (95% UI),
Thousands
Death PAFs,
% (95% UI)
DALYs,
No. (95% UI),
Thousands
DALY PAFs,
% (95% UI)
Deaths,
No. (95% UI),
Thousands
Death PAFs,
% (95% UI)
DALYs,
No. (95% UI),
Thousands
DALY PAFs,
% (95% UI)
All-cause
deaths
and DALYs
10 704
(9601-11 787)
19.18
(17.21-21.11)
211 816
(192 712-231 114)
8.61
(7.66-9.55)
7834
(6973-8706)
14.04
(12.51-15.55)
143 037
(130 198-156 961)
5.81
(5.14-6.48)
Ischemic
heart disease
4862
(3955-5740)
54.53
(44.39-64.23)
90 298
(77 837-102 138)
55.05
(47.29-62.29)
3573
(2867-4277)
40.08
(32.28-48.14)
61 736
(52 823-70 417)
37.64
(32.13-43.10)
Ischemic stroke 1489
(1167-1821)
49.98
(39.43-60.76)
24 198
(19 500-28 264)
53.52
(43.61-61.89)
1134
(879-1399)
38.07
(29.89-46.65)
17 653
(14 135-20 671)
39.05
(31.63-45.15)
Hemorrhagic
stroke
1953
(1588-2313)
58.32
(47.94-68.53)
43 412
(36 092-49 999)
59.13
(49.03-67.41)
1423
(1152-1705)
42.51
(34.22-50.82)
29 708
(24 529-34 286)
40.46
(33.61-46.77)
Other
cardiovascular
diseasesb
1552
(1457-1653)
57.95
(54.97-61.02)
33 209
(30 711-36 020)
51.19
(48.21-54.37)
1151
(1054-1285)
42.98
(39.54-47.68)
22 472
(20 464-24 911)
34.65
(32.00-38.24)
Chronic
kidney disease
848
(759-925)
68.69
(63.72-73.49)
20 699
(18 196-22 879)
58.71
(54.00-63.16)
553
(494-608)
44.78
(40.98-48.29)
11 468
(10 005-12 803)
32.53
(29.33-35.52)
Abbreviations:DALYs, disability-adjusted life years; PAFs, population-attributable
fractions;UI, uncertainty interval.
a All data are for year 2015, individuals aged 25 years and older, and both sexes
combined.
bCategory includes rheumatic heart disease, hypertensive heart disease,
cardiomyopathy andmyocarditis, atrial fibrillation and flutter, aortic
aneurysm, peripheral vascular disease, endocarditis, and other cardiovascular
and circulatory diseases.
Figure 2. Projected Global Disability-Adjusted Life-Years by Systolic Blood Pressure Level and Cause, 2015
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thosewith SBPof 140mmHgorhigher,whereas among those
aged 25 to 29 years, 30% of CVD burden is in those with SBP
of 140mmHg or higher.
Regional and Country Results
Figure 3 shows age-standardized DALY rates associated with
SBPofat least 110 to115mmHgfor21GBDregionsandbycause.
Regions were ordered by life expectancy. Age-standardized
DALYratesvaried substantially—from1025.66 (95%UI,916.51-
1136.97) in theAsia-Pacifichigh-incomeregion to7022.18 (95%
UI, 5259.73-9652.2) in Oceania. The variation in 2015 for SBP
of at least 110 to 115mmHgwas greater across countries rang-
ing from 923 DALYs (95% UI, 794-1046) per 100 000 in
Switzerland to 13 639 (95% UI, 10696-17 151) per 100000 in
Afghanistan (eTable 4 in the Supplement). Age-standardized
DALYs associated with SBP of at least 110 to 115 mm Hg were
highest in Oceania, Eastern Europe, Central Asia, and Central
sub-SaharanAfrica. Relative to life expectancy, the burden of
SBP was comparatively high in East Asia and Central Europe
(eTable4 in theSupplement). The relative contributionsofdif-
ferent outcomes to the global age-standardized DALY rate as-
sociated with SBP of at least 110 to 115 mm Hg varied by re-
gion. In sub-Saharan Africa, cerebrovascular diseases
predominated, while in Oceania, Central Asia, and Eastern
Europe, ischemic heart disease predominated.
Table 4 and Table 5 provide deaths and DALYs associated
with SBP 110 to 115mmHg and of 140mmHg or higher for all
ages and both sexes combined, by region, and for the 25most
populous countries in the world from 1990 to 2015. The last
column in Table 4 and Table 5 lists the number of individuals
measured for each country for all included data sources.
Estimates for all countries can be found in eTables 2, 3, and 4
in the Supplement. The highest age-standardized death rate
was estimated for Afghanistan with 637 deaths (95% UI, 511-
579) per 100000, Vanuatu with 420 (95% UI, 309-584) per
100000,and Iraqwith415 (95%UI, 336-506)per 100000.The
lowest age-standardized rates of SBP-related deaths were in
Andorra with 61 (95% UI, 51-71) per 100000, France with 62
(95% UI, 54-72) per 100000, and Canada with 64 (95% UI,
53-75) per 100000. The age-standardized mortality rate for
womenwas 145 (95%UI, 129-162) per 100000vs 197 (95%UI,
176-217) per 100000 for men (eTable 6 in the Supplement).
Of the global burden of 212 million DALYs related to SBP
of at least 110 to 115 mm Hg, 60% occurred in 10 countries,
with the majority of DALYs in China with 45.1 million and in
India with 38.7 million (Figure 4). Age-standardized DALYs
from SBP decreased globally, but the trend varied between
countries. Although age-standardized DALYs per capita asso-
ciated with SBP of at least 110 to 115 mm Hg decreased
between 1990 and 2015 in South Korea by 77.2% (95% UI,
75.6%-78.8%) and in the the United Kingdom by 65.6%
(95% UI, 64.1%-67.1%), a significant increase of 18.9% (95%
UI, 1.6%-41.4%) was observed in Bangladesh. Countries in
sub-Saharan Africa (except Southern sub-Saharan Africa),
Table 3. Projected Number of Deaths and Disability-Adjusted Life-Years Related to Systolic Blood Pressure of at Least 110 to 115mmHg
and of 140mmHg or Higher by Age and by Sex in 2015
Age
Group, y
SBP, Men SBP, Women
≥110-115 mm Hg ≥140 mm Hg ≥110-115 mm Hg ≥140 mm Hg
Deaths,
No. (95% UI),
Thousands
DALYs,
No. (95% UI),
Thousands
Deaths,
No. (95% UI),
Thousands
DALYs,
No. (95% UI),
Thousands
Deaths,
No. (95% UI),
Thousands
DALYs,
No. (95% UI),
Thousands
Deaths,
No. (95% UI),
Thousands
DALYs,
No. (95% UI),
Thousands
25-29 38
(30-47)
2468
(1967-2992)
11
(8-15)
718
(505-950)
15
(12-19)
1049
(823-1317)
3
(2-4)
181
(126-249)
30-34 68
(57-79)
3960
(3326-4565)
37
(30-45)
2148
(1722-2607)
25
(21-30)
1556
(1290-1873)
9
(7-12)
558
(430-711)
35-39 94
(82-108)
4982
(4326-5660)
52
(44-61)
2725
(2323-3208)
36
(30-42)
1994
(1679-2334)
15
(12-18)
799
(649-988)
40-44 143
(123-164)
6776
(5847-7780)
76
(64-89)
3595
(3034-4222)
59
(50-68)
2929
(2462-3377)
26
(22-32)
1300
(1072-1570)
45-49 235
(205-266)
9954
(8712-11 220)
136
(118-157)
5764
(4988-6646)
107
(93-121)
4721
(4076-5314)
57
(48-66)
2481
(2117-2892)
50-54 352
(313-391)
13 179
(11 752-14 638)
219
(193-246)
8200
(7252-9238)
172
(153-192)
6654
(5906-7392)
102
(90-114)
3911
(3452-4409)
55-59 465
(420-510)
15 148
(13 706-16 573)
309
(278-341)
10 075
(9065-11 121)
246
(222-269)
8297
(7510-9100)
162
(146-179)
5427
(4882-6015)
60-64 643
(584-700)
17 890
(16 237-19 456)
451
(408-494)
12 535
(11 298-13 720)
381
(349-414)
10 898
(9946-11 880)
270
(244-294)
7698
(6958-8392)
65-69 629
(552-697)
14 567
(12 778-16 115)
455
(397-506)
10 532
(9190-11 755)
449
(400-495)
10 581
(9406-11 671)
338
(300-375)
7962
(7036-8836)
70-74 727
(627-813)
13 548
(11 684-15 125)
544
(470-613)
10 110
(8705-11 342)
603
(527-669)
11 404
(9955-12 664)
474
(413-529)
8950
(7761-9995)
75-79 751
(667-834)
10 796
(9608-11 962)
571
(507-640)
8196
(7231-9174)
715
(637-793)
10 370
(9257-11 450)
568
(506-634)
8228
(7308-9199)
≥80 1449
(1168-1717)
10 958
(8874-12 942)
1100
(886-1313)
8316
(6697-9901)
2278
(1833-2699)
15 549
(12 548-18 291)
1848
(1489-2187)
12 629
(10 204-14 914)
All agesa 5608
(5073-6156)
125 124
(113 463-136 730)
3963
(3564-4372)
82 915
(75 255-90 813)
5096
(4503-5671)
86 692
(78 653-94 918)
3872
(3406-4337)
60 122
(54 210-66 029)
Abbreviation: DALYs, disability-adjusted life-years.
a Indicates individuals aged 25 years and older.
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South Asia, Central Asia, Southeast Asia, and Central Latin
America generally increased in age-standardized DALYs per
capita associated with SBPs of at least 110 to 115 mm Hg. In
China, the total burden of SBP has increased since 1990, and
SBP levels increased after 1995 but were offset by decreases
in mortality until 2005, at which point the overall age-
standardized burden started increasing.
Discussion
In this study,weusedanexpandedsetofbloodpressurepreva-
lence surveys toassess, for the first time toourknowledge, the
full distribution of the population by level of SBP and the bur-
den ofmortality and DALYs associated with each level of SBP
for 195 countries and territories. This study showed that SBP
of at least 110 to 115 mm Hg was associated with more than
10 million deaths (95% UI, 9.6-11.8 million) and more than
212millionDALYs (95%UI, 193-231million) in 2015, a 1.4-fold
increase since 1990. Compared with all other specific risks
quantified in theGBD, SBPof at least 110 to 115mmHgwas the
leadingglobalcontributor topreventabledeath in2015.10These
estimates are concerning given that in 2015, an estimated
3.5 billion individuals had an SBP level of at least 110 to
115 mmHg.
This analysis, the first to be performed at a comprehen-
sive global scale, found considerable variation among the 195
countries and territories and 21 regions studied. Five coun-
tries accounted formore than half of global DALYs associated
with SBP of at least 110 to 115 mm Hg: China, India, Russia,
Indonesia, and the United States. Both the projected number
andprevalence rateofSBPofat least 110 to 115mmHgare likely
to continue to increase globally. These findings support in-
creased efforts to control the burden of SBP of at least 110 to
115 mmHg to reduce disease burden.
In this study, ischemic heart disease and stroke ac-
counted for themajority of health loss (DALYs,which include
deaths and nonfatal burden) related to SBP of at least 110 to
115 mm Hg. Although the majority of the burden associated
with SBP occurred in persons with hypertension (SBP
≥140mmHg), nearly 30%occurred in individualswith anSBP
between 115 and 140 mm Hg. A broad range of other condi-
tions contributed tohealth loss associatedwith SBPof at least
110 to 115mmHg,with chronic kidneydiseasenotable for con-
tributing almost asmanyDALYs globally in 2015 as hyperten-
sive heart disease.
There have been claims that the burden of SBP of at least
110 to 115 mm Hg is an increasing problem globally.4,5,8,45
The finding that the totalprojectednumberof individualswith
SBP of 140 mm Hg or higher is increasing globally supports
those claims. Although the drivers of trends in hypertension
were not quantified in this study, other research has docu-
mented that dietary salt intake, fruit andvegetable consump-
tion, overweight and obesity, and physical activity have also
changed substantially over the same time period.10 Among
these factors at the global scale, the prevalence of obesity and
Figure 3. Projected Age-Standardized Disability-Adjusted Life-Years by Systolic Blood Pressure of at Least 110
to 115mmHg, by Region and Cause, 2015
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overweight in particular increased substantially over the pe-
riod 1990 to 2015.20
With population growth and aging and the fact that SBP
levels increase with age, the number of persons with hyper-
tension and related adverse health outcomes are expected to
increase in the world. Despite the increase in global SBP lev-
els in termsofnumbers (per individualwithSBP≥140mmHg),
rates, and age-standardized rates of SBP of 140 mm Hg or
higher, deaths and DALYs associated with SBP of at least 110
to 115 mm Hg and SBP of 140 mm Hg or higher have de-
creased. The difference in trends between exposure to SBP of
at least 110 to 115 mmHg and the rates of related outcomes is
likely related to background trends downward in global age-
specific cardiovascular death rates. Previous studies have at-
tributed those declines in CVD death rates to changes in risk
factors such as tobacco as well as improved access to
treatment.46-48 Although declines in elevated blood pressure
may have contributed to CVD declines in some high-income
countries such as Japan, globally, the downward trend in hy-
pertension is not a driver of CVD rate reductions.49 Yet SBP of
at least 110 to 115mmHg remains oneof the larger risks for de-
creasedhumanhealth, greater than tobaccoorhighbodymass
index, forwhich SBPprobablymediates a portion of the risk.9
Prevention and control of highbloodpressure through a com-
bination of behavioral, lifestyle, and drug treatment strate-
gies as ahealth systempriority couldmitigate thegrowingbur-
den associated with high SBP.
The results of the current study are informed by, but do
not help to resolve, the significant debate about appropriate
clinical use and targets for blood pressure–lowering medica-
tions.Meta-analyses performedbyLawet al andEttehad et al
showed cardiovascular mortality benefits for a target SBP as
low as 120 mm Hg.31,32 SPRINT showed significant mortality
benefits among individuals in the United States with el-
evated cardiovascular risk, 90%ofwhomwere already receiv-
ing prior treatment with blood pressure–lowering medica-
tion, when they received intensive blood pressure reduction
therapyandachievedanaverageSBPbelow120mmHg.38The
HOPE-3 trial did not observe this same benefit when less in-
tensive bloodpressure reductionwas achieved.However, un-
like the SPRINT trial, the population enrolled in HOPE-3 had
an initial mean SBP of 138mmHg (and only 22%were receiv-
ing prior treatment with blood pressure–lowering medica-
tions),more tobacco smokers, andmorewomen. Inaprespeci-
fied analysis, HOPE-3 found benefit only among thosewhose
SBP remained above 143 mmHg.
These results support the model assumption that el-
evatedSBP is amodifiable risk factor formortalityeven though
the precise subpopulation and SBP target for blood pressure–
lowering medications remains less clear. The purpose of this
Figure 4. Projected Global Disability-Adjusted Life-Years by Systolic Blood Pressure Level
and Country or Region, 2015
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super regions from the Global Burden
of Diseases, Injuries, and Risk Factors
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the United States, China, and India
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representation of the following
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studywas to estimate the full extent of health burden lost re-
lated to elevated SBP and not to determine the optimum SBP
level for the current population. This estimation is an essen-
tial step inunderstanding the contributionof SBPas a risk fac-
tor for global health loss. Quantification of the modifiable
health loss due to SBP, given scale-upof the technologies cur-
rently available for SBP lowering, would require an alternate
estimation strategy thanused for this study.However in 2015,
7.8milliondeaths and 143millionDALYswere estimated to be
related to SBP of 140 mm Hg or higher, suggesting that large
health gains from expanded treatment with blood pressure–
lowering medications are possible. It is likely that more evi-
dence will be needed to define the role of pharmacotherapy
in reducing the burden associated with SBP of at least
110 mmHg and less than an SBP of 140mmHg.
This study has important limitations. First, the burden of
highdiastolic bloodpressure, including cases of isolatedhigh
diastolicbloodpressure,wasnot included.Second,burdenwas
only associated with SBP for individuals aged 25 years and
older, except for hypertensive heart disease, which included
all ages. Third, estimates of populationmean SBPwere based
on 814 studies in 154 countries. For 41 countries with no ex-
aminationsurveydata, estimatesofbloodpressure levelswere
based on spatiotemporal Gaussian process regression statis-
tical models; there is a need for population-based health sur-
veys in these countries as well as broader implementation of
surveys that trackaccess to treatment. Fourth,measured stan-
dard deviations of blood pressure were converted to nar-
rower ranges of usual blood pressure using a single correc-
tion factor based on cohort studies in 5 countries.10 The
conversion from measurements taken at a given point in
time to usual blood pressure were based on an intertemporal
variation in SBP for each individual. This intertemporal varia-
tion may well vary across countries. Moreover, uncertainty
in this correctionwasnot captured in this study.Fifth, the rela-
tive risk of each 10-mm increment of SBP was assumed to be
the same from115mmHgtoSBPabove200mmHg.Themeta-
analyses by Lv et al and by Law et al of all blood pressure–
lowering trials support this assumption; showing that there
was no statistically different RR as a function of starting level
of SBP.31,50 Sixth, the RRs for each outcome were assumed
to be generalizable across populations. Higher RRs have been
reported for 6 countries in the East Asia, high-income
AsiaPacific, andAustralasia regions includingChina (andHong
Kong), Japan, New Zealand, Singapore, South Korea, and
Taiwan.35,51,52 Other studies found RRs varied by race.7,53,54
Large cohort pooling studies are required to establish statis-
tically significant location- and time-specific RRs. While ac-
knowledging these limitations, this study was based on the
largest available set of data and applied the samemethods to
previous years to provide a consistent analysis of time trends
from 1990 to 2015.
Conclusions
In international surveys, although there isuncertainty in some
estimates, the prevalence of elevated SBP (≥110-115 and
≥140mmHg) increased substantially between 1990and2015,
with a corresponding increase in DALYs and deaths associ-
atedwith elevated SBP. Projections based on this sample sug-
gest that in 2015, an estimated 3.5 billion adults had SBP of at
least 110 to 115 mm Hg and 874 million adults had SBP of
140mmHg or higher.
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